Ticker	Volume	Price	Price Delta
DJIA	15,307.20	-80.41	-0.52%
S&P 500	1,655.35	-13.81	-0.83%
Nasdaq	3,463.30	-38.82	-1.11%

Ticker

Volume

Price

Price Delta

DJIA

15,307.20

-80.41

-0.52%

S&P 500

1,655.35

-13.81

-0.83%

Nasdaq

3,463.30

-38.82

-1.11%

Ticker	Volume	Price	Price Delta
STOXX 50	2,835.01	+13.36	0.47%
FTSE 100	6,840.27	+36.40	0.53%
DAX	8,530.89	+58.69	0.69%

Ticker

Volume

Price

Price Delta

STOXX 50

2,835.01

+13.36

0.47%

FTSE 100

6,840.27

+36.40

0.53%

DAX

8,530.89

+58.69

0.69%

Ticker	Volume	Price	Price Delta
Nikkei	15,627.30	+246.24	1.60%
Hang Seng	23,261.10	-105.29	-0.45%
S&P/ASX 200	5,165.37	-14.69	-0.28%

Ticker

Volume

Price

Price Delta

Nikkei

15,627.30

+246.24

1.60%

Hang Seng

23,261.10

-105.29

-0.45%

S&P/ASX 200

5,165.37

-14.69

-0.28%

Exchange: Berlin
Sector: Consumer, Non-cyclical
Industry: Pharmaceuticals
Sub-Industry: Drug Delivery Systems

Elite Pharmaceuticals Inc

+ Add to Watchlist

ETF:GR

0.049 EUR 0.0000.00%

Share this quote:

Post this quote on one of these sites:

Copy permanent URL

As of 02:08:26 ET on 05/22/2013.

Snapshot for Elite Pharmaceuticals Inc (ETF)

Open:	0.049	Day's Range:	0.049 - 0.049	Volume:	0
Previous Close:	0.049	52wk Range:	0.046 - 0.112	1-Yr Rtn:	-38.75%

Stock Chart for ETF

No chart data available.

ETF:GR 0.049

0.049

Interactive ETF Chart

…

Previous Close

Key Statistics for ETF

Current P/E Ratio (ttm)	-
Estimated P/E(-)	-
Relative P/E vs. DAX	-
Earnings Per Share (ttm)	-
Est. EPS	-
Est. PEG Ratio	-
Market Cap (M EUR)	0.00
Shares Outstanding (M)	0.00
30 Day Average Volume	0
Price/Book (mrq)	-
Price/Sale (ttm)	-
Dividend Indicated Gross Yield	-%
Cash Dividend	-
Last Dividend
5 Year Dividend Growth	-
Next Earnings Announcement	07/01/2013

mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for ETF

Revenue
Net Income (M/USD)

Profit Margin (%)

Company Profile & Key Executives for ETF

Elite Pharmaceuticals, Inc. researches, develops, licenses, and manufactures both new and generic oral controlled-release pharmaceutical products. The Company has pain products in clinical trials and has developed products incorporating therapeutic agents such as cardiovasculars, antidiabetic, cough and cold preparations, and anti-infectives.